The FDA has granted a priority review to the supplemental Biologics License Application for enfortumab/pembrolizumab to all ...
Dr. Premal Thaker reports IMNN-001 shows early survival benefit in ovarian cancer by activating immune response directly in ...
First patient dosing occurred for JANX011 (NCT07291323), a CD19-targeted bispecific inaugurating the ARM platform to enable ...
Liquid biopsy ctDNA reveals targets and flags residual disease in esophageal and gastric cancers, hinting at earlier relapse ...
In this episode of The OncoloGIST, Dr Christine Bestvina of UChicago Medicine provides a comprehensive look at the rapidly ...
On-body injector isatuximab enables at-home myeloma treatment, cutting infusion visits, easing time and financial strain, and ...
Molecular subclassification has effectively converted lung cancer into many biologically distinct entities, making comprehensive, up-to-date biomarker interpretation indispensable for selecting ...
Matthew Powell, MD, discusses long-term overall survival results with dostarlimab plus chemo in dMMR endometrial cancer ...
Limited proactive offering of video visits by oncology teams, especially for nonusers, reduced exposure and normalized ...
MSK researchers found that BRCA2 mutations lower the barrier for RB1 loss, causing CDK4/6 inhibitor resistance.
In this episode of Community Corner, Christopher H. Lieu, MD, professor of medicine at the University of Colorado Cancer ...
T-cell therapy is the most efficacious approach for many patients with relapsed/refractory multiple myeloma, but it currently comes with 2 periods ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results